BUND FINANCE › Stocks › ROIV
Roivant Sciences Ltd. (ROIV)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +3.77% above its 50-day average.
- It is +19.24% above its 200-day average (long-term uptrend).
- It sits at 83% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$55.3M | US$31.5M | US$32.7M | US$29.1M | US$8.3M |
| Net income | −US$845.3M | −US$1.0B | US$4.3B | −US$172.0M | −US$299.8M |
| EPS (diluted) | -1.26 | -1.42 | 5.23 | -0.24 | -0.43 |
| Gross margin | 83.8% | 90.4% | 95.1% | 96.9% | 84.4% |
| Operating margin | -2,191.8% | -2,565.9% | -2,521.7% | -3,833.3% | -15,560.6% |
| Net margin | -1,528.9% | -3,200.2% | 13,294.2% | -592.0% | -3,629.2% |
| Free cash flow | −US$695.2M | −US$856.1M | −US$766.7M | −US$844.1M | −US$758.6M |
| Total debt | US$283.9M | US$481.4M | US$499.7M | US$100.2M | US$107.4M |
| Cash | US$2.1B | US$1.7B | US$6.5B | US$2.7B | US$1.4B |
Compound annual growth: revenue -37.8% · net income — (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | 1.9x | 27.1x |
| EV / EBITDA | — | 0.5x | 16.5x |
| Operating margin | -3,233.0% | — | 3.6% |
| Net margin | -838.2% | — | -0.0% |
| Debt / equity | 0.09 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bac…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice